Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.34 |
| ▸ | AOC2 | O75106 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980634 | 0.93 | NFE2L2 (0.38) | NFE2L2MAOBMAOASOS1HSPB1 | |
| SCHEMBL7867836 | 0.74 | IDO1 (0.33) | — | |
| SCHEMBL5828142 | 0.74 | — | — | |
| SCHEMBL95870 | 0.74 | NFE2L2 (0.41) | NFE2L2MAOBMAOASOS1HSPB1 | |
| SCHEMBL1259185 | 0.74 | NFE2L2 (0.46) | NFE2L2MAOBMAOASOS1HSPB1 | |
| SCHEMBL13665332 | 0.74 | SOS1 (0.43) | NFE2L2MAOBMAOASOS1HSPB1 | |
| SCHEMBL8495621 | 0.74 | ACHE (0.48) | ALDH1A1L3MBTL1CA1CA2CA7 | |
| SCHEMBL410307 | 0.74 | NFE2L2 (0.41) | NFE2L2MAOBMAOASOS1HSPB1 | |
| SCHEMBL6570976 | 0.74 | CYP2A6 (0.42) | MAOBMAOAALDH1A1L3MBTL1CA1 | |
| SCHEMBL2494427 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | claimed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | claimed |
| CN-117903022-A | Application of zirconium hydroxide as catalyst in preparing sulfoxide and sulfone by selective catalytic oxidation of thioether | 兰州大学 | 2024-04-19 | — | — | CN | disclosed |
| US-7138538-B2 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY (SOCIETE ANONYME) (BE) | 2006-11-21 | — | — | US | disclosed |
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | SOLVAY S.A. (BE) | 2004-10-21 | — | — | US | disclosed |
| EP-1046627-B1 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (BE) | 2004-02-11 | — | — | EP | disclosed |
| EP-1046627-A2 | Enantiopure reagents and process for the separation of enantiomers | SOLVAY (Société Anonyme) (BE) | 2000-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210060-A1 | Process for the separation of enantiomers and enantiopure reagent | DNPEP, DAO, ANPEP | NFE2L2 1858/4885MAOB 168/4885MAOA 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.